With increasing information overload and packed work schedules, staying up-to-date on the newest oncologic advances is harder than ever. But take heart! The QuadShot is freshly brewed in your inbox four mornings each week so you can quickly down and digest the day's most pertinent cancer news.
It always knows. We’re smelling a big upcoming market entry for the HER2-TKI tucatinib with more evidence of its safety, this time in combo with Kadcyla in this phase 1b trial. |Borges, JAMA Oncol 2018